Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryuta Kojima

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 29, 2024
Cytokine release syndrome following durvalumab and tremelimumab in advanced hepatocellular carcinoma: A case report with cytokine and damage-associated molecular pattern analysisTomomi Ozaki, Sae Yumita, Sadahisa Ogasawara, et al.
International Immunopharmacology|March 31, 2023
Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinomaNa Qiang, Junjie Ao, Masato Nakamura, et al.
Journal of Cancer|April 15, 2021
Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinomaJunjie Ao, Tetsuhiro Chiba, Hiroaki Kanzaki, et al.
Drugs - Real World Outcomes|July 19, 2023
Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective AnalysisHiroaki Kanzaki, Sadahisa Ogasawara, Tomomi Okubo, et al.
BMJ Open|April 9, 2022
Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trialSadahisa Ogasawara, Keisuke Koroki, Hirokazu Makishima, et al.
International Journal of Clinical Oncology|June 15, 2022
Liver biopsy technique in the era of genomic cancer therapies: a single-center retrospective analysisYusuke Ozeki, Naoya Kanogawa, Sadahisa Ogasawara, et al.
JHEP Reports : Innovation in Hepatology|December 9, 2025
The efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in relation to tumor-infiltrating lymphocytesHiroaki Kanzaki, Takamasa Ishino, Sadahisa Ogasawara, et al.
BMC Gastroenterology|March 11, 2023
Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinomaNaoya Kanogawa, Sadahisa Ogasawara, Susumu Maruta, et al.
BMC Gastroenterology|April 2, 2023
Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practiceSae Yumita, Sadahisa Ogasawara, Miyuki Nakagawa, et al.
Cancer|November 25, 2022
Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practiceMiyuki Nakagawa, Masanori Inoue, Sadahisa Ogasawara, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 29, 2024
Cytokine release syndrome following durvalumab and tremelimumab in advanced hepatocellular carcinoma: A case report with cytokine and damage-associated molecular pattern analysisTomomi Ozaki, Sae Yumita, Sadahisa Ogasawara, et al.
International Immunopharmacology|March 31, 2023
Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinomaNa Qiang, Junjie Ao, Masato Nakamura, et al.
Journal of Cancer|April 15, 2021
Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinomaJunjie Ao, Tetsuhiro Chiba, Hiroaki Kanzaki, et al.
Drugs - Real World Outcomes|July 19, 2023
Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective AnalysisHiroaki Kanzaki, Sadahisa Ogasawara, Tomomi Okubo, et al.
BMJ Open|April 9, 2022
Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trialSadahisa Ogasawara, Keisuke Koroki, Hirokazu Makishima, et al.
International Journal of Clinical Oncology|June 15, 2022
Liver biopsy technique in the era of genomic cancer therapies: a single-center retrospective analysisYusuke Ozeki, Naoya Kanogawa, Sadahisa Ogasawara, et al.
JHEP Reports : Innovation in Hepatology|December 9, 2025
The efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in relation to tumor-infiltrating lymphocytesHiroaki Kanzaki, Takamasa Ishino, Sadahisa Ogasawara, et al.
BMC Gastroenterology|March 11, 2023
Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinomaNaoya Kanogawa, Sadahisa Ogasawara, Susumu Maruta, et al.
BMC Gastroenterology|April 2, 2023
Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practiceSae Yumita, Sadahisa Ogasawara, Miyuki Nakagawa, et al.
Cancer|November 25, 2022
Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practiceMiyuki Nakagawa, Masanori Inoue, Sadahisa Ogasawara, et al.
Pageof 2